Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global inflammatory bowel disease treatment market size was exhibited at USD 20.35 billion in 2022 and is projected to hit around USD 29.27 billion by 2032, growing at a CAGR of 3.7% during the forecast period 2023 to 2032.

inflammatory bowel disease treatment market size

Key Pointers:

  • The Crohn’s disease segment held the largest share of 60.11% of the market in 2022 
  • In 2022, the injectable segment held the largest market share of 77.9% 
  • The hospital pharmacies segment captured a 46.2% revenue share of the IBD treatment market in 2022. 
  • The Crohn’s disease segment held the largest share owing to the increasing prevalence of the condition and the high prescription rate of biologics for the treatment of the disease
  • The ulcerative colitis segment is poised to register the fastest growth rate due to the rising approval of biologics for the treatment of ulcerative colitis and the high patient base
  • The TNF inhibitors segment accounted for the largest market share in 2022 owing to the high prescription rate for the treatment of IBD and rising consumer awareness about TNF inhibitors
  • Based on the route of administration, the injectable segment dominated the inflammatory bowel disease treatment market in 2022, whereas the oral segment is anticipated to be the fastest-growing segment
  • Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the rising investments by market players and increasing disease prevalence in the region

Inflammatory Bowel Disease Treatment Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 21.1 Billion

Market Size by 2032

USD 29.27 Billion

Growth Rate from 2023 to 2032

CAGR of 3.7%

Base year

2022

Forecast period

2023 to 2032

Segments covered

Type, Drug class, Distribution channel, Route of administration

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

AbbVie Inc; Takeda Pharmaceutical Company Limited; Pfizer Inc; Biogen; Novartis AG; Lilly; UCB S.A.; CELLTRION INC.; Merck & Co., Inc; Johnson & Johnson Services, Inc.

 

The increasing prevalence of the disease, the surge in awareness about inflammatory bowel disease among people, and favorable regulatory scenarios are projected to drive the inflammatory bowel disease treatment market over the forecast period. For instance, in December 2022, Pfizer Inc. announced the U.S. FDA acceptance for review of an NDA for etrasimod for patients having severe ulcerative colitis. The favorable initiatives undertaken by regulatory authorities for treatment designations and approval of novel drugs for the management of inflammatory bowel disease are fueling market expansion.

The increasing collaboration of market players and non-profit organizations to counter various challenges in the development of novel therapeutics for IBD treatment is projected to propel market growth. For instance, in October 2022, Verily, a precision health company and the Crohn’s & Colitis Foundation expanded their strategic collaboration to accelerate research in ulcerative colitis and Crohn’s disease. In addition, the European Crohn’s and Colitis Organization has taken several favorable steps to improve the care of patients living with inflammatory bowel disease.

Recently approved novel drugs such as filgotinib, ozanimod, upadacitinib, and risankizumab for the treatment of inflammatory bowel disease are expected to support market growth in the coming years. Moreover, the regulatory authorities are encouraging manufacturers to develop novel therapeutic approaches for rare and life-threatening diseases. For instance, in December 2020, Thetis Pharmaceuticals received an orphan drug designation for TP-317 from the U.S. FDA for pediatric ulcerative colitis. Such favorable initiatives are expected to boost the R&D activities to develop novel therapeutic products for IBD.

Furthermore, the rising demand & approvals for biosimilars for the treatment of various inflammatory conditions is a high-impact rendering factor for the market. For instance, in December 2022, the U.S. FDA approved Idacio as an eighth adalimumab biosimilar in the U.S. The newly approved biosimilar is a citrate-free low-concentration preparation intended for the treatment of several inflammatory conditions, including CD in adults and children aged 6 years or older. In addition, in October 2021, the U.S. FDA approved Cyltezo for the management of moderate to severe CD and UC. Moreover, the increasing introduction of biosimilars is expected to boost the adoption of biological products for the treatment of IBD in developing economies.

Moreover, government bodies are taking efforts to promote the uptake of biosimilars with their safe use. For instance, in October 2022, the government of Saskatchewan launched a biosimilar initiative to help its residents to access high-quality therapeutics at a lesser cost. Similarly, provinces like Ontario and Quebec in Canada are also expanding biosimilar initiatives to promote the uptake of biosimilar candidates.

Inflammatory Bowel Disease Treatment Market Segmentation

By Type By Drug Class  By Route of Administration By Distribution Channel
  • Crohn's Disease
  • Ulcerative Colitis
  • Aminosalicylates
  • Corticosteroids
  • TNF inhibitors
  • IL inhibitors
  • Anti-integrin
  • JAK inhibitors
  • Others
  • Oral
  • Injectable
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Frequently Asked Questions

The global inflammatory bowel disease treatment market size was exhibited at USD 20.35 billion in 2022 and is projected to hit around USD 29.27 billion by 2032

The global IBD treatment market is expected to grow at a compound annual growth rate of 3.7% from 2023 to 2032

Some key players operating in the IBD treatment market include Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead Sciences among others.

Key factors that are driving the IBD treatment market growth include the increasing prevalence of Crohn\'s disease & ulcerative colitis, presence of strong pipeline products, and increasing adoption of biological products.

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation and Scope
                       1.1.1 Segment scope
                       1.1.2 Regional scope
                       1.1.3 Estimates and forecast timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database:
                       1.3.2 Nova one advisor’s internal database
                       1.3.3 Secondary sources
                       1.3.4 Primary research
                       1.3.5 Details of primary research
                   1.4 Information or Data Analysis
                       1.4.1 Data analysis models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis
                       1.6.1.1 Approach: Commodity Flow Approach
                   1.7 Research Assumptions
                   1.8 List of Secondary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective 1
                       1.10.2 Objective 2
                       1.10.3 Objective 3
                       1.10.4 Objective 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Competitive Insights
Chapter 3 Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market
                   3.2 Market Dynamics
                       3.2.1 Market drivers analysis
                           3.2.1.1 Robust product pipeline
                           3.2.1.2 High prevalence of crohn’s disease and ulcerative colitis
                           3.2.1.3 Increasing geriatric population
                       3.2.2 Market restraint analysis
                           3.2.2.1 High number of patent expirations
                           3.2.2.2 High cost of treatment
                   3.3 Penetration & Growth Prospect Mapping
                   3.4 Gastrointestinal Therapeutics: Market Analysis Tools
                       3.4.1 Industry analysis- Porter’s
                       3.4.2 PESTLE analysis
                   3.5 Regulatory Framework
                   3.6 Pricing Analysis
Chapter 4 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Type, 2022 - 2032
                   4.1 Definition and Scope
                   4.2 Type Market Share Analysis, 2022 & 2032
                   4.3 Segment Dashboard
                   4.4 Global Inflammatory Bowel Disease Treatment Market, by Type, 2022 to 2032
                   4.5 Market Size & Forecasts and Trend Analyses, 2022 to 2032
                       4.5.1 Crohn's Disease
                           4.5.1.1 Crohn's disease market estimates and forecast, 2022 - 2032
                       4.5.2 Ulcerative Colitis
                           4.5.2.1 Ulcerative colitis market estimates and forecast, 2022 - 2032
Chapter 5 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Drug Class 2022 - 2032
                   5.1 Definition and Scope
                   5.2 Drug Class Market Share Analysis, 2022 & 2032
                   5.3 Segment Dashboard
                   5.4 Global Inflammatory Bowel Disease Treatment Market, by Drug Class, 2022 to 2032
                   5.5 Market Size & Forecasts and Trend Analyses, 2022 to 2032
                       5.5.1 Aminosalicylates
                           5.5.1.1 Aminosalicylates market estimates and forecast, 2022 - 2032
                       5.5.2 Corticosteroids
                           5.5.2.1 Corticosteroids market estimates and forecast, 2022 - 2032
                       5.5.3 TNF inhibitors
                           5.5.3.1 TNF inhibitors market estimates and forecast, 2022 - 2032
                       5.5.4 IL inhibitors
                           5.5.4.1 IL inhibitors market estimates and forecast, 2022 - 2032
                       5.5.5 Anti-integrin
                           5.5.5.1 Anti-integrin market estimates and forecast, 2022 - 2032
                       5.5.6 JAK inhibitors
                           5.5.6.1 JAK inhibitors market estimates and forecast, 2022 - 2032
                       5.5.7 Others
                           5.5.7.1 Others market estimates and forecast, 2022 - 2032
Chapter 6 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Route of Administration, 2022 - 2032
                   6.1 Definition and Scope
                   6.2 Route of Administration Market Share Analysis, 2022 & 2032
                   6.3 Segment Dashboard
                   6.4 Global Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2022 to 2032
6.5 Market Size & Forecasts and Trend Analyses, 2022 to 2032
                       6.5.1 Oral
                           6.5.1.1 Oral market estimates and forecast, 2022 - 2032
                       6.5.2 Injectable
                           6.5.2.1 Injectable market estimates and forecast, 2022 - 2032
Chapter 7 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Distribution Channel, 2022 - 2032
                   7.1 Definition and Scope
                   7.2 Distribution Channel Market Share Analysis, 2022 & 2032
                   7.3 Segment Dashboard
                   7.4 Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2022 to 2032
                   7.5 Market Size & Forecasts and Trend Analyses, 2022 to 2032
                       7.5.1 Hospital Pharmacy
                           7.5.1.1 Hospital pharmacy market estimates and forecast, 2022 - 2032
                       7.5.2 Retail Pharmacy
                           7.5.2.1 Retail pharmacy market estimates and forecast, 2022 - 2032
                       7.5.3 Online Pharmacy
                           7.5.3.1 Online pharmacy market estimates and forecast, 2022 - 2032
Chapter 8 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Region, 2022 - 2032
                   8.1 Definition & Scope
                   8.2 Regional Market Share Analysis, 2022 & 2032
                   8.3 Regional Market Dashboard
                   8.4 Regional Market Snapshot
                   8.5 SWOT Analysis
                       8.5.1 North America
                       8.5.2 Europe
                       8.5.3 Asia Pacific
                       8.5.4 Latin America
                       8.5.5 Middle East and Africa
                   8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2032
                       8.6.1 North America
                           8.6.1.1 North America inflammatory bowel disease treatment market , 2022 - 2032
                           8.6.1.2 U.S.
                               8.6.1.2.1 Key Country Dynamics
                               8.6.1.2.2 Competitive Scenario
                               8.6.1.2.3 Regulatory Framework
                               8.6.1.2.4 Reimbursement Scenario
                               8.6.1.2.5 U.S. inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.1.3 Canada
                               8.6.1.3.1 Key Country Dynamics
                               8.6.1.3.2 Competitive Scenario
                               8.6.1.3.3 Regulatory Framework
                               8.6.1.3.4 Reimbursement Scenario
                               8.6.1.3.5 Canada inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                       8.6.2 Europe
                           8.6.2.1 Europe inflammatory bowel disease treatment market, 2022 - 2032
                           8.6.2.2 UK
                               8.6.2.2.1 Key Country Dynamics
                               8.6.2.2.2 Competitive Scenario
                               8.6.2.2.3 Regulatory Framework
                               8.6.2.2.4 Reimbursement Scenario
                               8.6.2.2.5 UK inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.3 Germany
                               8.6.2.3.1 Key Country Dynamics
                               8.6.2.3.2 Competitive Scenario
                               8.6.2.3.3 Regulatory Framework
                               8.6.2.23.4 Reimbursement Scenario
                               8.6.2.3.5 Germany inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.4 Spain
                               8.6.2.4.1 Key Country Dynamics
                               8.6.2.4.2 Competitive Scenario
                               8.6.2.4.3 Regulatory Framework
                               8.6.2.4.4 Reimbursement Scenario
                               8.6.2.4.5 Spain inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.5 France
                               8.6.2.5.1 Key Country Dynamics
                               8.6.2.5.2 Competitive Scenario
                               8.6.2.5.3 Regulatory Framework
                               8.6.2.5.4 Reimbursement Scenario
                               8.6.2.5.5 France inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.6 Italy
                               8.6.2.6.1 Key Country Dynamics
                               8.6.2.6.2 Competitive Scenario
                               8.6.2.6.3 Regulatory Framework
                               8.6.2.6.4 Reimbursement Scenario
                               8.6.2.6.5 Italy inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.7 Denmark
                               8.6.2.7.1 Key Country Dynamics
                               8.6.2.7.2 Competitive Scenario
                               8.6.2.7.3 Regulatory Framework
                               8.6.2.7.4 Reimbursement Scenario
                               8.6.2.7.5 Denmark inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.8 Sweden
                               8.6.2.8.1 Key Country Dynamics
                               8.6.2.8.2 Competitive Scenario
                               8.6.2.8.3 Regulatory Framework
                               8.6.2.8.4 Reimbursement Scenario
                               8.6.2.8.5 Sweden inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.2.9 Norway
                               8.6.2.9.1 Key Country Dynamics
                               8.6.2.9.2 Competitive Scenario
                               8.6.2.9.3 Regulatory Framework
                               8.6.2.9.4 Reimbursement Scenario
                               8.6.2.9.5 Norway inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                       8.6.3 Asia Pacific
                           8.6.3.1 Asia Pacific inflammatory bowel disease treatment market, 2022 - 2032
                           8.6.3.2 Japan
                               8.6.3.2.1 Key Country Dynamics
                               8.6.3.2.2 Competitive Scenario
                               8.6.3.2.3 Regulatory Framework
                               8.6.3.2.4 Reimbursement Scenario
                               8.6.3.2.5 Japan inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.3.3 China
                               8.6.3.3.1 Key Country Dynamics
                               8.6.3.3.2 Competitive Scenario
                               8.6.3.3.3 Regulatory Framework
                               8.6.3.3.4 Reimbursement Scenario
                               8.6.3.3.5 China inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.3.4 India
                               8.6.3.4.1 Key Country Dynamics
                               8.6.3.4.2 Competitive Scenario
                               8.6.3.4.3 Regulatory Framework
                               8.6.3.4.4 Reimbursement Scenario
                               8.6.3.4.5 India inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.3.5 South Korea
                               8.6.3.5.1 Key Country Dynamics
                               8.6.3.5.2 Competitive Scenario
                               8.6.3.5.3 Regulatory Framework
                               8.6.3.5.4 Reimbursement Scenario
                               8.6.3.25.5 South Korea inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.3.6 Australia
                               8.6.3.6.1 Key Country Dynamics
                               8.6.3.6.2 Competitive Scenario
                               8.6.3.6.3 Regulatory Framework
                               8.6.3.6.4 Reimbursement Scenario
                               8.6.3.6.5 Australia inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.3.7 Thailand
                               8.6.3.7.1 Key Country Dynamics
                               8.6.3.7.2 Competitive Scenario
                               8.6.3.7.3 Regulatory Framework
                               8.6.3.7.4 Reimbursement Scenario
                               8.6.3.7.5 Thailand inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.3.8 Singapore
                               8.6.3.8.1 Key Country Dynamics
                               8.6.3.8.2 Competitive Scenario
                               8.6.3.8.3 Regulatory Framework
                               8.6.3.8.4 Reimbursement Scenario
                               8.6.3.8.5 Thailand inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                       8.6.4 Latin America
                           8.6.4.1 Latin America inflammatory bowel disease treatment market, 2022 - 2032
                           8.6.4.2 Brazil
                               8.6.4.2.1 Key Country Dynamics
                               8.6.4.2.2 Competitive Scenario
                               8.6.4.2.3 Regulatory Framework
                               8.6.4.2.4 Reimbursement Scenario
                               8.6.4.2.5 Brazil inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.4.3 Mexico
                               8.6.4.3.1 Key Country Dynamics
                               8.6.4.3.2 Competitive Scenario
                               8.6.4.3.3 Regulatory Framework
                               8.6.4.3.4 Reimbursement Scenario
                               8.6.4.3.5 Mexico inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.4.4 Argentina
                               8.6.4.4.1 Key Country Dynamics
                               8.6.4.4.2 Competitive Scenario
                               8.6.4.4.3 Regulatory Framework
                               8.6.4.4.4 Reimbursement Scenario
                               8.6.4.4.5 Argentina inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                       8.6.5 MEA
                           8.6.5.1 MEA inflammatory bowel disease treatment market, 2022 - 2032
                           8.6.5.2 South Africa
                               8.6.5.2.1 Key Country Dynamics
                               8.6.5.2.2 Competitive Scenario
                               8.6.5.2.3 Regulatory Framework
                               8.6.5.2.4 Reimbursement Scenario
                               8.6.5.2.5 South Africa inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.5.3 Saudi Arabia
                               8.6.5.3.1 Key Country Dynamics
                               8.6.5.3.2 Competitive Scenario
                               8.6.5.3.3 Regulatory Framework
                               8.6.5.3.4 Reimbursement Scenario
                               8.6.5.3.5 Saudi Arabia inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.5.4 UAE
                               8.6.5.4.1 Key Country Dynamics
                               8.6.5.4.2 Competitive Scenario
                               8.6.5.4.3 Regulatory Framework
                               8.6.5.4.4 Reimbursement Scenario
                               8.6.5.4.5 UAE inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
                           8.6.5.5 Kuwait
                               8.6.5.5.1 Key Country Dynamics
                               8.6.5.5.2 Competitive Scenario
                               8.6.5.5.3 Regulatory Framework
                               8.6.5.5.4 Reimbursement Scenario
                               8.6.5.5.5 Kuwait inflammatory bowel disease treatment market estimates and forecast, 2022 - 2032
Chapter 9 Inflammatory Bowel Disease Treatment Market- Competitive Analysis
                   9.1 Recent Developments & Impact Analysis, by Key Market Participants
                       9.1.1 Ansoff matrix
                       9.1.2 Heat map analysis
                       9.1.3 Major Deals and Strategic Alliances Analysis
                           9.1.3.1 Joint Ventures
                           9.1.3.2 Licensing Agreements
                           9.1.3.3 Product Launches
                           9.1.3.4 Conferences and Campaigns
                   9.2 Company Categorization
                       9.2.1 Innovators
                       9.2.2 Market Leaders
                   9.3 Vendor Landscape
                       9.3.1 List of key distributors and channel partners
                       9.3.2 Key customers
                   9.4 Public Companies
                       9.4.1 Competitive Dashboard Analysis
                           9.4.1.1 Market Differentiators
                   9.5 Private Companies
                       9.5.1 List of key emerging companies
                   9.6 Company Profiles
                       9.6.1 AbbVie Inc
                           9.6.1.1 Company overview
                           9.6.1.2 Financial performance
                           9.6.1.3 Product benchmarking
                           9.6.1.4 Strategic Initiatives
                       9.6.2 Biogen
                           9.6.2.1 Company overview
                           9.6.2.2 Financial performance
                           9.6.2.3 Product benchmarking
                           9.6.2.4 Strategic Initiatives
                       9.6.3 Takeda Pharmaceutical Company Limited
                           9.6.3.1 Company overview
                           9.6.3.2 Financial performance
                           9.6.3.3 Product benchmarking
                           9.6.3.4 Strategic Initiatives
                       9.6.4 Novartis AG
                           9.6.4.1 Company overview
                           9.6.4.2 Financial performance
                           9.6.4.3 Product benchmarking
                           9.6.4.4 Strategic Initiatives
                       9.6.5 Pfizer Inc
                           9.6.5.1 Company overview
                           9.6.5.2 Financial performance
                           9.6.5.3 Product benchmarking
                           9.6.5.4 Strategic Initiatives
                       9.6.6 Lilly
                           9.6.6.1 Company overview
                           9.6.6.2 Financial performance
                           9.6.6.3 Product benchmarking
                           9.6.6.4 Strategic Initiatives
                       9.6.7 UCB S.A.
                           9.6.7.1 Company overview
                           9.6.7.2 Financial performance
                           9.6.7.3 Product benchmarking
                           9.6.7.4 Strategic initiatives
                       9.6.8 Johnson & Johnson Services, Inc.
                           9.6.8.1 Company overview
                           9.6.8.2 Financial performance
                           9.6.8.3 Product benchmarking
                           9.6.8.4 Strategic initiatives
                       9.6.9 CELLTRION INC
                           9.6.9.1 Company overview
                           9.6.9.2 Financial performance
                           9.6.9.3 Product benchmarking
                           9.6.9.4 Strategic initiatives
                       9.6.10 Merck & Co., Inc
                           9.6.10.1 Company overview
                           9.6.10.2 Financial performance
                           9.6.10.3 Product benchmarking
                           9.6.10.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3900
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert